Background: The anti-inflammatory potential of antihistamines has significant clinical utility. Long-term pharmacotherapy of so-called ‘safe’ antihistamines may be hampered by side effects in the central nervous system. In the present study, the new potential antihistamine SUN-1334H was compared with different antihistamines for anti-inflammatory effects, sedation potential and interaction with alcohol. Method: Nasal and skin allergy were induced in guinea pig and mice by ovalbumin sensitization and challenge. Neurogenic nasal inflammation was induced by capsaicin. Sedation potential and interaction with alcohol were assessed by i.v. and intracerebroventricular pentobarbital-induced sedation and alcohol-induced ataxia models. Results: Ovalbumin sensitization and challenge caused rhinitis pathology including inflammatory cell infiltration, IL-4, and protein leakage in the nasal lavage fluid (NLF) and presence of inflammatory cells in nasal epithelium. A 5-day treatment of antihistamines reduced these markers of inflammation. SUN-1334H, cetirizine and hydroxyzine caused comparable inhibition of NLF leukocytes, IL-4 and total protein concentrations. Fexofenadine and desloratadine showed moderate inhibition of NLF leukocytes and had no significant effect on IL-4 concentration. While fexofenadine had no effect on total protein concentration, the effect of desloratadine was comparable with the other antihistamines. In neurogenic nasal inflammation induced by capsaicin, SUN-1334H and fexofenadine caused better inhibition at lower and middle dose levels than the other antihistamines. In skin allergy models, SUN-1334H showed potent reduction of passive and active cutaneous anaphylactic reactions. In central nervous system side effects models, SUN-1334H, desloratadine and fexofenadine were devoid of any significant effects. Conclusions: The results are suggestive of a high anti-inflammatory to sedation index of SUN-1334H among leading antihistamines.

Keywords:
Anti-allergic, Antihistamine, Anti-inflammatory, Eosinophils, SUN-1334H
1.
Rosenwasser L: New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc 2007;28:10–15.
2.
Bousquet J, Chaenz P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel FB: Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033–1039.
3.
Terada N, Konno A, Togawa K: Biochemical properties of eosinophils and their preferential accumulation mechanism in nasal allergy. J Allergy Clin Immunol 1994;94:629–642.
4.
Kaminuma O, Mori A: Potential initiation of eosinophilic skin inflammation by antigen-specific T helper Type 2 cells. Int Arch Allergy Immunol 2002;128:21–23.
5.
Imai N, Miyahara A, Yamasaki Y, Homma R, Ino Y, Kurumi M: Involvement of eosinophils in the early-phase allergic reaction in a guinea pig rhinitis model. Int Arch Allergy Immunol 2000;122:270–278.
6.
Tartar M, Petriskova J, Zucha J, Pecova R, Hutka Z, Raffajova J, Brozmanova M: Induced sputum eosinophils, broncheal reactivity and cough sensitivity with allergic rhinitis. J Physol Pharmacol 2005;56:227–236.
7.
Gleich GJ, Adolphson CR, Leiferman KM: The biology of the eosinophilic leukocyte. Ann Rev Med 1993;44:85–101.
8.
Nonaka M, Nonaka R, Woolley K, Adelroth E, Miura K, Okhawara Y, Glibetic M, Nakano K, O’Byrne P, Dolovich J: Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues: IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995;155:3234–3244.
9.
Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA: Cytokine messenger RNA expression for IL-1, IL-4, IL-5, and granulocyte/macrophage-colony stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992;148:2390–2394.
10.
Moqbel R, Ying S, Barkans J, Newman TM, Kimmit P, Wakelin MW, Taborda-Barata L, Meng Q, Corrigan CJ, Durham SR: Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995;155:4939–4947.
11.
Moser R, Groscurth P, Carballido JM, Bruijnzeel PLB, Blaser K, Heusser CH, Fehr J: Interleukin-4 induces tissue eosinophilia in mice: correlation with its in vitro capacity to stimulate the endothelial cell dependent selective transmigration of human eosinophils. J Lab Clin Med 1993;122:567–575.
12.
Gao JX, Issekutz AC: Expression of VCAM-1 and VLA-4 dependent T-lymphocyte adhesion to dermal fibroblast stimulated with proinflammatory cytokines. Immunology 1996;89:375–383.
13.
Sanz MJ, Mutafchieva LM, Green P, Lobb RR, Feldmann M, Nourshargh S: IL-4-induced eosinophil accumulation in rat skin is dependent on endogenous TNF-α and α4 integrin/VCAM-1 adhesion pathways. J Immunol 1998;160:5637–5645.
14.
Delneste Y, Lassalle P, Jeannin P, Joseph M, Tonnel AB, Gosset P: Histamine induces IL-6 production by human endothelial cells. Clin Exp Immunol 1994;98:344–349.
15.
Mor S, Nagler A, Barak V, Handzel ZT, Geller-Bernstein C, Fabian I: Histamine enhances granulocyte colony-stimulating factor and interleukin-6 production by human peripheral blood mononuclear cells. J Leukoc Biol 1995;58:445–450.
16.
Jeannin P, Delneste Y, Gosset P, Molet S, Lassalle P, Hamid Q, Tsicopoulos A, Tonnel AB: Histamine induces interleukin-8 secretion by endothelial cells. Blood 1994;84:2229–2233.
17.
Howarth PH: A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy 2000;55:6–11.
18.
Gelfand EW, Appajosyula S, Meeves S: Anti-inflammatory activity of H1 receptor antagonists: review of recent experimental research. Curr Med Res Opin 2004;20:73–81.
19.
Walsh GM: Anti-inflammatory properties of antihistamines: an update. Clin Exp Allergy Rev 2005;5:21–25.
20.
Nettis E, Colanardi MC, Ferrannini A, Tursi A: Antihistamines as important tools for regulating inflammation. Curr Med Chem 2005;4:81–89.
21.
Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW: Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:507–511.
22.
Walsh GM: A review of role of levocetirizine as an effective therapy for allergic disease. Expert Opin Pharmacother 2008;9:859–867.
23.
Canning BJ: Neurology of allergic inflammation and rhinitis. Curr Allergy Asthma Rep 2002;2:210–215.
24.
Groneberg DA, Quarcoo D, Frossard N, Fischer A: Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 2004;59:1139–1152.
25.
Lundberg JM, Saria A: Capsaicin-induced desensitization of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 1983;302:251–253.
26.
Richardson DJ, Vasko MR: Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002;302:839–845.
27.
Kaise T, Akamatsu Y, Ohmori K, Ishii A, Karasawa A: Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs. Jpn J Pharmacol 2001;86:258–261.
28.
Watanabe T, Yanai K: Studies on functional roles of the histaminergic neuron system by using pharmacological agent, knock-out mice and positron emission tomography. Tohoku J Exp Med 2001;195:197–217.
29.
Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T: New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999;29:29–36.
30.
Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, Ito K, Itoh M: Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649–1655.
31.
Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Asakura M, Matsumura R, Itoh M: Positron emission tomographic study of central histamine H1 receptor occupancy in human subjects treated with epinastine, a second generation antihistamine. Meth Find Exp Clin Pharmacol 1995;17(suppl C):64–69.
32.
Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890–900.
33.
Holgate ST, Canonica GW, Simons FER, Taglialatela M, Tharp M, Timmerman H, Yanai K: Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33:1305–1324.
34.
Mandhane SN, Ayer UB, Midha AS, Rao CT, Rajamannar T: Preclinical efficacy and safety pharmacology of SUN-1334H, a potent orally active antihistamine agent. Drugs R D 2008;9:93–112.
35.
Bahekar PC, Shah JH, Ayer UB, Mandhane SN, Rajamannar T: Validation of guinea pig model of allergic rhinitis by oral and topical drugs. Int Immunopharmacol 2008;8:1540–1551.
36.
Yamasaki M, Sasaki K, Mizutani N, Nabe T, Sakura Y, Matsumoto T, Ashida Y, Kohno S: Pharmacological characterization of the leukocyte kinetics after intranasal antigen challenge in a guinea pig model of allergic rhinitis. Inflamm Res 2001;50:474–482.
37.
Iijima H, Tamura G, Hsiue T, Liu Y, Taniguchi H, Shirato K: Suplatast tosilate inhibits late response and airway inflammation in sensitized guinea pigs. Am J Respir Crit Care Med 1999;160:331–335.
38.
Saloga J, Renz H, Lack G, Bradley KL, Greenstein JL, Larsen G, Gelfand EW: Development and transfer of immediate cutaneous hypersensitivity in mice exposed to aerosolized antigen. J Clin Invest 1993;91:133–140.
39.
Mizutani N, Nabe T, Takinaka H, Kohno S: Acquired nasal hyperresponsiveness aggravates antigen-induced rhinitis in the guinea pig. J Pharmacol Sci 2003;93:437–445.
40.
Haley TJ, McCormick WG: Pharmacological effects produced by intra-cerebral injection of drugs in the conscious mouse. Br J Pharmacol 1957;12:12–15.
41.
Chambers DM, Jefferson DC: Some observations on the mechanism of benzodiazepine-barbiturate interactions in the mouse. Br J Pharmacol 1977;60:393–399.
42.
Holden NS, Gong W, King EM, Kaur M, Giembycz MA, Newton R: Potentiation of NF-kappa B-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells. Br J Pharmacol 2007;152:891–902.
43.
Roumestan C, Henriquet C, Gougat C, Michel A, Bichon F, Portet K, Jaffuel D, Mathieu M: Histamine H1-receptor antagonists inhibit nuclear factor-kappa B and activator protein-1 activities via H1-receptor-dependent and independent mechanisms. Clin Exp Allergy 2008;38:947–956.
44.
Arnold R, Rihoux J, Konig W: Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999;29:1681–1691.
45.
Yoneda K, Yamamoto T, Ueta E, Osaki T: Suppression by azelastine hydrochloride of NF-κB activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997;73:145–153.
46.
Ciprandi G, Passalacqua G, Canonica GW: Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 1999;29:49–53.
47.
Buscaglia S, Paolieri F, Catrullo A, Fiorino N, Riccio AM, Pesce G, Montagna P, Bagnasco M, Ciprandi G, Canonica GW: Topical ocular levocabastine reduces ICAM-1 expression on epithelial calls both in vivo and vitro. Clin Exp Allergy 1996;26:1188–1196.
48.
Bensch GW, Nelson HS, Borish LC: Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann Allergy Asthma Immunol 2002;88:457–462.
49.
Kips JC, Tournoy KG, Pauwels RA: New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5. Eur Respir J 2001;17:499–506.
50.
Brusselle GG, Kips JC, Tavernier JH, Van Der Heyden JG, Cuvelier CA, Pauwels RA, Bluethmann H: Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1993;24:73–80.
51.
Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA, McIntyre BW, Bochner BS: IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992;148:1086–1092.
52.
Ciprandi G, Cirillo I, Bizzaccaro A, Tosca MA: Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 2004;34:958–964.
53.
Montoro J, Sastre J, Jauregui I, Bartra J, Davila I, del Cuvillo A, Ferrer M, Mullol J, Valero A: Allergic rhinitis: continuous or on demand antihistamine therapy? J Investig Allergol Clin Immunol 2007;17:21–27.
54.
Weg VB, Watson ML, Cordeiro RS, Williams TJ: Histamine, leukotriene D4 and platelet-activating factor in guinea pig passive cutaneous anaphylaxis. Eur J Pharmacol 1991; 204:157–163.
55.
Simons FER, Silver NA, Gu X, Simons KJ: Clinical pharmacology of H1 antihistamines in the skin. J Allergy Clin Immunol 2002;110:777–783.
56.
Geppetti P, Fusco BM, Marabini S, Maggi CA, Fanciullacci M, Sicuteri F: Secretion, pain and sneezing induced by the application of capsaicin to the nasal mucosa in man. Br J Pharmacol 1988;93:509–514.
57.
Bascom R, Kagey-Sobotka A, Proud D: Effect of intranasal capsaicin on symptoms and mediator release. J Pharmacol Exp Ther 1991;259:1323–1327.
58.
Di Maria GU, Bellofiore S, Geppetti P: Regulation of airway neurogenic inflammation by neutral endopeptidase. Eur Respir J 1998;12:1454–1462.
59.
Steinbach JH, Akk G: Modulation of GABA (A) receptor channel gating by pentobarbital. J Physiol 2001;537:715–733.
60.
Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y: Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425–461.
61.
Chen C, Hanson E, Watson JW, Lee JS: P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003;31:312–318.
62.
Tahara H, Kusuhara H, Fuse E, Sugiyama Y: P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005;33:963–968.
63.
Ramaekers JG, Uiterwijk MM, O’Hanlon JF: Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992;42:363–369.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.